Marco Presta

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4501649/publications.pdf

Version: 2024-02-01

343 papers	18,629 citations	10351 72 h-index	18075 120 g-index
346 all docs	346 docs citations	346 times ranked	16854 citing authors

#	Article	IF	Citations
1	FGFR blockade by pemigatinib treats naÃ¯ve and castration resistant prostate cancer. Cancer Letters, 2022, 526, 217-224.	3.2	8
2	Oncosuppressive and oncogenic activity of the sphingolipid-metabolizing enzyme Î²-galactosylceramidase. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188675.	3.3	6
3	Production and Biochemical Characterization of Dimeric Recombinant Gremlin-1. International Journal of Molecular Sciences, 2022, 23, 1151.	1.8	3
4	Î²-Galactosylceramidase in cancer: more than a psychosine scavenger. Oncoscience, 2022, 9, 11-12.	0.9	1
5	The FGF/FGFR system in the physiopathology of the prostate gland. Physiological Reviews, 2021, 101, 569-610.	13.1	37
6	A novel variant of VEGFR2 identified by a pan-cancer screening of recurrent somatic mutations in the catalytic domain of tyrosine kinase receptors enhances tumor growth and metastasis. Cancer Letters, 2021, 496, 84-92.	3.2	7
7	Halting the FGF/FGFR axis leads to antitumor activity in WaldenstrÃ¶m macroglobulinemia by silencing MYD88. Blood, 2021, 137, 2495-2508.	0.6	4
8	Avian Reovirus P17 Suppresses Angiogenesis by Promoting DPP4 Secretion. Cells, 2021, 10, 259.	1.8	7
9	Endogenous Long Pentraxin 3 Exerts a Protective Role in a Murine Model of Pulmonary Fibrosis. Frontiers in Immunology, 2021, 12, 617671.	2.2	11
10	VEGF-Independent Activation of MÃ¼ller Cells by the Vitreous from Proliferative Diabetic Retinopathy Patients. International Journal of Molecular Sciences, 2021, 22, 2179.	1.8	18
11	Simultaneously characterization of tumoral angiogenesis and vasculogenesis in stem cell-derived teratomas. Experimental Cell Research, 2021, 400, 112490.	1.2	2
12	Pentraxin 3 Inhibits the Angiogenic Potential of Multiple Myeloma Cells. Cancers, 2021, 13, 2255.	1.7	6
13	Inactive VEGFR2(R1032Q) exerts proâ€oncogenic activity through heterodimerization with wildâ€type receptor. FASEB Journal, 2021, 35, .	0.2	0
14	Caffeine Inhibits Direct and Indirect Angiogenesis in Zebrafish Embryos. International Journal of Molecular Sciences, 2021, 22, 4856.	1.8	15
15	Expression of activated VEGFR2 by R1051Q mutation alters the energy metabolism of Sk-Mel-31 melanoma cells by increasing glutamine dependence. Cancer Letters, 2021, 507, 80-88.	3.2	8
16	Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity. Blood, 2021, 138, 1705-1720.	0.6	10
17	Î²-Galactosylceramidase in cancer: friend or foe?. Trends in Cancer, 2021, 7, 974-977.	3.8	5
18	Vitreous from idiopathic epiretinal membrane patients induces glial-to-mesenchymal transition in MÃ¼ller cells. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 166181.	1.8	6

#	Article	IF	Citations
19	Chemical modification of NSC12 leads to a specific FGF-trap with antitumor activity in multiple myeloma. European Journal of Medicinal Chemistry, 2021, 221, 113529.	2.6	3
20	Quantification of Tumor Vasculature by Analysis of Amount and Spatial Dispersion of Caliber-Classified Vessels. Methods in Molecular Biology, 2021, 2206, 151-178.	0.4	0
21	Fibroblast Growth Factors. , 2021, , 1-11.		0
22	Fibroblast Growth Factors. , 2021, , 665-675.		0
23	Human iPSC modelling of a familial form of atrial fibrillation reveals a gain of function of If and ICaL in patient-derived cardiomyocytes. Cardiovascular Research, 2020, 116, 1147-1160.	1.8	50
24	Î²-Galactosylceramidase Deficiency Causes Bone Marrow Vascular Defects in an Animal Model of Krabbe Disease. International Journal of Molecular Sciences, 2020, 21, 251.	1.8	5
25	The nanostructured secretome. Biomaterials Science, 2020, 8, 39-63.	2.6	36
26	Angiogenesis-Inflammation Cross Talk in Diabetic Retinopathy: Novel Insights From the Chick Embryo Chorioallantoic Membrane/Human Vitreous Platform. Frontiers in Immunology, 2020, 11, 581288.	2.2	37
27	Î²-Galactosylceramidase Promotes Melanoma Growth via Modulation of Ceramide Metabolism. Cancer Research, 2020, 80, 5011-5023.	0.4	12
28	In Situ DNA/Protein Interaction Assay to Visualize Transcriptional Factor Activation. Methods and Protocols, 2020, 3, 80.	0.9	3
29	Inhibition of the FGF/FGFR System Induces Apoptosis in Lung Cancer Cells via c-Myc Downregulation and Oxidative Stress. International Journal of Molecular Sciences, 2020, 21, 9376.	1.8	24
30	Gene expression analysis identifies two distinct molecular clusters of idiopatic epiretinal membranes. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165938.	1.8	11
31	d-Peptide analogues of Boc-Phe-Leu-Phe-Leu-Phe-COOH induce neovascularization via endothelial N-formyl peptide receptor 3. Angiogenesis, 2020, 23, 357-369.	3.7	8
32	Long-Pentraxin 3 Affects Primary Cilium in Zebrafish Embryo and Cancer Cells via the FGF System. Cancers, 2020, 12, 1756.	1.7	6
33	Modeling Acquired Resistance to the Second-Generation Androgen Receptor Antagonist Enzalutamide in the TRAMP Model of Prostate Cancer. Cancer Research, 2020, 80, 1564-1577.	0.4	10
34	FGF Trapping Inhibits Multiple Myeloma Growth through c-Myc Degradationâ€“Induced Mitochondrial Oxidative Stress. Cancer Research, 2020, 80, 2340-2354.	0.4	41
35	Zebrafish embryo as an experimental model to study tumor angiogenesis. , 2020, , 129-145.		6
36	Targeting the Endothelin-1 Receptors Curtails Tumor Growth and Angiogenesis in Multiple Myeloma. Frontiers in Oncology, 2020, 10, 600025.	1.3	9

#	Article	IF	Citations
37	FGF/FGFR Axis-Blockade Leads to Anti-Tumor Activity in Waldenstrom's Macroglobulinemia By Silencing MYD88. Blood, 2020, 136, 43-44.	0.6	1
38	VEGFR2 activation mediates the pro-angiogenic activity of BMP4. Angiogenesis, 2019, 22, 521-533.	3.7	33
39	Long Pentraxin-3 Follows and Modulates Bladder Cancer Progression. Cancers, 2019, 11, 1277.	1.7	24
40	The Autocrine FGF/FGFR System in both Skin and Uveal Melanoma: FGF Trapping as a Possible Therapeutic Approach. Cancers, 2019, 11, 1305.	1.7	18
41	PTX3 Modulates Neovascularization and Immune Inflammatory Infiltrate in a Murine Model of Fibrosarcoma. International Journal of Molecular Sciences, 2019, 20, 4599.	1.8	14
42	Vascular Endothelial Growth Factor in the Vitreous of Proliferative Diabetic Retinopathy Patients: Chasing a Hiding Prey?. Diabetes Care, 2019, 42, e105-e106.	4.3	13
43	Atypical Chemokine Receptor 3 Generates Guidance Cues for CXCL12-Mediated Endothelial Cell Migration. Frontiers in Immunology, 2019, 10, 1092.	2.2	9
44	Circulating microRNAs and Their Role in Multiple Myeloma. Non-coding RNA, 2019, 5, 37.	1.3	10
45	Quantification of 3D Brain Microangioarchitectures in an Animal Model of Krabbe Disease. International Journal of Molecular Sciences, 2019, 20, 2384.	1.8	6
46	Human vitreous in proliferative diabetic retinopathy: Characterization and translational implications. Progress in Retinal and Eye Research, 2019, 72, 100756.	7.3	91
47	Zebrafish disease models in hematology: Highlights on biological and translational impact. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 620-633.	1.8	18
48	Specific Targeting of KRAS Using a Novel High-Affinity KRAS Antisense Oligonucleotide in Multiple Myeloma. Blood, 2019, 134, 3104-3104.	0.6	2
49	Overcoming the Supportive Stroma-Induced Proliferation in Waldenstrom's Macroglobulinemia By Selective Inhibition of the FGF/FGF-Receptor Axis. Blood, 2019, 134, 1822-1822.	0.6	0
50	N-tert-butyloxycarbonyl-Phe-Leu-Phe-Leu-Phe (BOC2) inhibits the angiogenic activity of heparin-binding growth factors. Angiogenesis, 2018, 21, 47-59.	3.7	27
51	Long pentraxin 3: A novel multifaceted player in cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2018, 1869, 53-63.	3.3	65
52	Long Pentraxin 3-Mediated Fibroblast Growth Factor Trapping Impairs Fibrosarcoma Growth. Frontiers in Oncology, 2018, 8, 472.	1.3	24
53	Vascular amounts and dispersion of caliber-classified vessels as key parameters to quantitate 3D micro-angioarchitectures in multiple myeloma experimental tumors. Scientific Reports, 2018, 8, 17520.	1.6	5
54	Long Pentraxin-3 Modulates the Angiogenic Activity of Fibroblast Growth Factor-2. Frontiers in Immunology, 2018, 9, 2327.	2.2	60

#	Article	IF	Citations
55	Editorial overview: Lymphatic vessels: More than a draining pipeline. Current Opinion in Immunology, 2018, 53, vii-ix.	2.4	1
56	Future applications of FGF/FGFR inhibitors in cancer. Expert Review of Anticancer Therapy, 2018, 18, 861-872.	1.1	76
57	Dendritic cells in inflammatory angiogenesis and lymphangiogenesis. Current Opinion in Immunology, 2018, 53, 180-186.	2.4	37
58	Claudin3 is localized outside the tight junctions in human carcinomas. Oncotarget, 2018, 9, 18446-18453.	0.8	15
59	Inflammation and N-formyl peptide receptors mediate the angiogenic activity of human vitreous humour in proliferative diabetic retinopathy. Diabetologia, 2017, 60, 719-728.	2.9	33
60	FGF Ligand Traps for the Therapy of FGF-Dependent Tumors. , 2017, , 237-269.		0
61	Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach. , 2017, 179, 171-187.		152
62	3D endothelial cell spheroid/human vitreous humor assay for the characterization of anti-angiogenic inhibitors for the treatment of proliferative diabetic retinopathy. Angiogenesis, 2017, 20, 629-640.	3.7	16
63	Contribution of vascular endothelial growth factor receptor-2 sialylation to the process of angiogenesis. Oncogene, 2017, 36, 6531-6541.	2.6	33
64	The importance of the genomic landscape in WaldenstrÃ¶m's Macroglobulinemia for targeted therapeutical interventions. Oncotarget, 2017, 8, 35435-35444.	0.8	4
65	U94 of human herpesvirus 6 down-modulates Src, promotes a partial mesenchymal-to-epithelial transition and inhibits tumor cell growth, invasion and metastasis. Oncotarget, 2017, 8, 44533-44549.	0.8	11
66	Fibroblast growth factor modulates mast cell recruitment in a murine model of prostate cancer. Oncotarget, 2017, 8, 82583-82592.	0.8	31
67	Monomeric gremlin is a novel vascular endothelial growth factor receptor-2 antagonist. Oncotarget, 2016, 7, 35353-35368.	0.8	34
68	Endothelial cell dysfunction in globoid cell leukodystrophy. Journal of Neuroscience Research, 2016, 94, 1359-1367.	1.3	14
69	Zebrafish (Danio rerio) embryo as a platform for the identification of novel angiogenesis inhibitors of retinal vascular diseases. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 1291-1296.	1.8	35
70	Synthesis, Structural Elucidation, and Biological Evaluation of NSC12, an Orally Available Fibroblast Growth Factor (FGF) Ligand Trap for the Treatment of FGF-Dependent Lung Tumors. Journal of Medicinal Chemistry, 2016, 59, 4651-4663.	2.9	29
71	COSMOS-rice technology abrogates the biotoxic effects of municipal solid waste incinerator residues. Environmental Pollution, 2016, 214, 713-721.	3.7	11
72	Evaluation of the Biotoxicity of Tree Wood Ashes in Zebrafish Embryos. Zebrafish, 2016, 13, 449-455.	0.5	5

#	Article	IF	Citations
73	SIGMAR1 Regulates Membrane Electrical Activity in Response to Extracellular Matrix Stimulation to Drive Cancer Cell Invasiveness. Cancer Research, 2016, 76, 607-618.	0.4	42
74	Blocking the FGF/FGFR system as a â¿¿two-compartmentâ¿¿ antiangiogenic/antitumor approach in cancer therapy. Pharmacological Research, 2016, 107, 172-185.	3.1	69
75	Synthetic Site-Selectively Mono-6-O-Sulfated Heparan Sulfate Dodecasaccharide Shows Anti-Angiogenic Properties In Vitro and Sensitizes Tumors to Cisplatin In Vivo. PLoS ONE, 2016, 11, e0159739.	1.1	8
76	Antiangiogenic Effectiveness of the Urokinase Receptor-Derived Peptide UPARANT in a Model of Oxygen-Induced Retinopathy. , 2015, 56, 2392.		31
77	The broad-spectrum anti-DNA virus agent cidofovir inhibits lung metastasis of virus-independent, FGF2-driven tumors. Oncotarget, 2015, 6, 4633-4648.	0.8	10
78	A tool for the quantification of radial neo-vessels in chick chorioallantoic membrane angiogenic assays. , 2015, 2015, 763-6.		1
79	Therapeutic Potential of Anti-Angiogenic Multitarget N,O-Sulfated E. Coli K5 Polysaccharide in Diabetic Retinopathy. Diabetes, 2015, 64, 2581-2592.	0.3	21
80	The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis. Expert Opinion on Therapeutic Targets, 2015, 19, 1361-1377.	1.5	72
81	Long-Pentraxin 3 Derivative as a Small-Molecule FGF Trap for Cancer Therapy. Cancer Cell, 2015, 28, 225-239.	7.7	111
82	Total reflection Xâ€Ray fluorescence spectroscopy to study Pb and Zn accumulation in zebrafish embryos. X-Ray Spectrometry, 2015, 44, 124-128.	0.9	19
83	Brain angioarchitecture and intussusceptive microvascular growth in a murine model of Krabbe disease. Angiogenesis, 2015, 18, 499-510.	3.7	36
84	Î² ₃ Integrin Promotes Long-Lasting Activation and Polarization of Vascular Endothelial Growth Factor Receptor 2 by Immobilized Ligand. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 2161-2171.	1.1	16
85	Angiogenic growth factors interactome and drug discovery: The contribution of surface plasmon resonance. Cytokine and Growth Factor Reviews, 2015, 26, 293-310.	3.2	26
86	Zebrafish Embryo Intersegmental Vessels: A Tool for Investigating Sprouting Angiogenesis. Methods in Molecular Biology, 2015, 1214, 173-184.	0.4	11
87	A long pentraxin-3-derived pentapeptide for the therapy of FGF8b-driven steroid hormone-regulated cancers. Oncotarget, 2015, 6, 13790-13802.	0.8	27
88	The role of the endothelium in globoid-cell leukodystrophy: unexpected revelations. Future Neurology, 2014, 9, 127-130.	0.9	1
89	Molecular cloning and knockdown of galactocerebrosidase in zebrafish: New insights into the pathogenesis of Krabbe's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 665-675.	1.8	26
90	In vitro and ex vivo retina angiogenesis assays. Angiogenesis, 2014, 17, 429-442.	3.7	76

#	Article	IF	Citations
91	Biosafe inertization of municipal solid waste incinerator residues by COSMOS technology. Journal of Hazardous Materials, 2014, 279, 311-321.	6.5	25
92	Cyclic Adenosine Monophosphate-Response Elementâ€“Binding Protein Mediates the Proangiogenic or Proinflammatory Activity of Gremlin. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 136-145.	1.1	45
93	Angiostatic, tumor inflammatory and anti-tumor effects of CXCL447-70 and CXCL4L147â€“70 in an EGF-dependent breast cancer model. Oncotarget, 2014, 5, 10916-10933.	0.8	23
94	Zebrafish embryo as a tool to study tumor/endothelial cell cross-talk. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 1371-1377.	1.8	45
95	TR-644 a novel potent tubulin binding agent induces impairment of endothelial cells function and inhibits angiogenesis. Angiogenesis, 2013, 16, 647-662.	3.7	33
96	A novel exÂvivo murine retina angiogenesis (EMRA) assay. Experimental Eye Research, 2013, 112, 51-56.	1.2	30
97	Involvement of Î±vÎ²3 integrin in gremlin-induced angiogenesis. Angiogenesis, 2013, 16, 235-243.	3.7	42
98	Matrigel plug assay: evaluation of the angiogenic response by reverse transcription-quantitative PCR. Angiogenesis, 2013, 16, 469-477.	3.7	38
99	Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell crossâ€talk in the bone marrow of multiple myeloma patients. Journal of Pathology, 2013, 229, 87-98.	2.1	34
100	Ascorbic acid rescues cardiomyocyte development in Fgfr1â^'/â^' murine embryonic stem cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2013, 1833, 140-147.	1.9	11
101	Long Pentraxin-3 Inhibits Epithelialâ€“Mesenchymal Transition in Melanoma Cells. Molecular Cancer Therapeutics, 2013, 12, 2760-2771.	1.9	68
102	Inhibition of angiogenesis by Î²-galactosylceramidase deficiency in globoid cell leukodystrophy. Brain, 2013, 136, 2859-2875.	3.7	32
103	Long pentraxinâ€3 as an epithelialâ€“stromal fibroblast growth factorâ€targeting inhibitor in prostate cancer. Journal of Pathology, 2013, 230, 228-238.	2.1	64
104	Long Pentraxin 3/Tumor Necrosis Factor-Stimulated Gene-6 Interaction. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 696-703.	1.1	69
105	Sphingosine-1-Phosphate Receptor-1 Controls Venous Endothelial Barrier Integrity in Zebrafish. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, e104-16.	1.1	29
106	The Thymidine Phosphorylase Inhibitor 5â€²-O-Tritylinosine (KIN59) Is an Antiangiogenic Multitarget Fibroblast Growth Factor-2 Antagonist. Molecular Cancer Therapeutics, 2012, 11, 817-829.	1.9	21
107	The Zebrafish/Tumor Xenograft Angiogenesis Assay. , 2012, , 253-268.		0
108	Substrate-Immobilized HIV-1 Tat Drives VEGFR2/Îı _v Î² ₃ â€“Integrin Complex Formation and Polarization in Endothelial Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, e25-34.	1.1	15

#	Article	IF	Citations
109	Role of Nanomechanics in Canonical and Noncanonical Pro-angiogenic Ligand/VEGF Receptor-2 Activation. Journal of the American Chemical Society, 2012, 134, 14573-14579.	6.6	24
110	Anti-angiogenic activity of the flavonoid precursor 4-hydroxychalcone. European Journal of Pharmacology, 2012, 691, 125-133.	1.7	37
111	Direct and Allosteric Inhibition of the FGF2/HSPGs/FGFR1 Ternary Complex Formation by an Antiangiogenic, Thrombospondin-1-Mimic Small Molecule. PLoS ONE, 2012, 7, e36990.	1.1	40
112	Heparan Sulfate Proteoglycans Mediate the Angiogenic Activity of the Vascular Endothelial Growth Factor Receptor-2 Agonist Gremlin. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, e116-27.	1.1	62
113	Zebrafish embryo, a tool to study tumor angiogenesis. International Journal of Developmental Biology, 2011, 55, 505-509.	0.3	60
114	The natural compound n-butylidenephthalide derived from the volatile oil of Radix Angelica sinensis inhibits angiogenesis in vitro and in vivo. Angiogenesis, 2011, 14, 187-197.	3.7	69
115	Long Pentraxin-3 Inhibits FGF8b-Dependent Angiogenesis and Growth of Steroid Hormoneâ€“Regulated Tumors. Molecular Cancer Therapeutics, 2011, 10, 1600-1610.	1.9	53
116	Fibroblast growth factor 2â€antagonist activity of a longâ€pentraxin 3â€derived antiâ€angiogenic pentapeptide. Journal of Cellular and Molecular Medicine, 2010, 14, 2109-2121.	1.6	46
117	Nanoliter contact angle probes tumor angiogenic ligandâ€“receptor protein interactions. Biosensors and Bioelectronics, 2010, 26, 1571-1575.	5.3	14
118	Thrombospondin-1 as a Paradigm for the Development of Antiangiogenic Agents Endowed with Multiple Mechanisms of Action. Pharmaceuticals, 2010, 3, 1241-1278.	1.7	30
119	The COOH-Terminal Peptide of Platelet Factor-4 Variant (CXCL4L1/PF-4var47-70) Strongly Inhibits Angiogenesis and Suppresses B16 Melanoma Growth In vivo. Molecular Cancer Research, 2010, 8, 322-334.	1.5	41
120	Non-peptidic Thrombospondin-1 Mimics as Fibroblast Growth Factor-2 Inhibitors. Journal of Biological Chemistry, 2010, 285, 8733-8742.	1.6	70
121	Antiangiogenic Activity of a Neutralizing Human Single-Chain Antibody Fragment against Fibroblast Growth Factor Receptor 1. Molecular Cancer Therapeutics, 2010, 9, 3244-3253.	1.9	28
122	Gremlin is a novel agonist of the major proangiogenic receptor VEGFR2. Blood, 2010, 116, 3677-3680.	0.6	163
123	Anti-FGF2 approaches asÂaÂstrategy toÂcompensate resistance toÂanti-VEGF therapy: long-pentraxin 3Âas aÂnovel antiangiogenic FGF2-antagonist. European Cytokine Network, 2009, 20, 225-234.	1.1	76
124	Exploiting Surface Plasmon Resonance (SPR) Technology for the Identification of Fibroblast Growth Factor-2 (FGF2) Antagonists Endowed with Antiangiogenic Activity. Sensors, 2009, 9, 6471-6503.	2.1	17
125	A proâ€inflammatory signature mediates FGF2â€induced angiogenesis. Journal of Cellular and Molecular Medicine, 2009, 13, 2083-2108.	1.6	66
126	Fibroblast growth factor 2â€induced angiogenesis in zebrafish: the zebrafish yolk membrane (ZFYM) angiogenesis assay. Journal of Cellular and Molecular Medicine, 2009, 13, 2061-2068.	1.6	58

#	Article	IF	Citations
127	Fibroblast growth factor receptorâ€1 phosphorylation requirement for cardiomyocyte differentiation in murine embryonic stem cells. Journal of Cellular and Molecular Medicine, 2009, 13, 1489-1498.	1.6	11
128	Impact of VEGFâ€dependent tumour microâ€environment on EDB fibronectin expression by subcutaneous human tumour xenografts in nude mice. Journal of Pathology, 2009, 219, 455-462.	2.1	17
129	Delivering cytokines at tumor site: The immunocytokine-conjugated anti-EDB-fibronectin antibody case. Immunobiology, 2009, 214, 800-810.	0.8	26
130	Inflammatory cells andÂchemokines sustain FGF2-induced angiogenesis. European Cytokine Network, 2009, 20, 39-50.	1.1	114
131	HIV-1 Tat and heparan sulfate proteoglycan interaction: a novel mechanism of lymphocyte adhesion and migration across the endothelium. Blood, 2009, 114, 3335-3342.	0.6	42
132	Fibroblast Growth Factor-2 Antagonist and Antiangiogenic Activity of Long-Pentraxin 3-Derived Synthetic Peptides. Current Pharmaceutical Design, 2009, 15, 3577-3589.	0.9	33
133	The adaptor protein p66shc is a positive regulator in the angiogenic response induced by hypoxic T cells. Journal of Leukocyte Biology, 2009, 87, 365-369.	1.5	11
134	New insights in the modulation of tumor angiogenesis. European Cytokine Network, 2009, 20, 157-157.	1.1	0
135	Fibroblast growth factor-2 binding to the thrombospondin-1 type III repeats, a novel antiangiogenic domain. International Journal of Biochemistry and Cell Biology, 2008, 40, 700-709.	1.2	67
136	Î±vÎ²3 Integrin-dependent antiangiogenic activity of resveratrol stereoisomers. Molecular Cancer Therapeutics, 2008, 7, 3761-3770.	1.9	40
137	Modulation of Angiogenesis by a Tetrameric Tripeptide That Antagonizes Vascular Endothelial Growth Factor Receptor 1. Journal of Biological Chemistry, 2008, 283, 34250-34259.	1.6	33
138	Angiopoietin-1 mediates the proangiogenic activity of the bone morphogenic protein antagonist Drm. Blood, 2008, 112, 1154-1157.	0.6	37
139	Calcitonin receptor-like receptor guides arterial differentiation in zebrafish. Blood, 2008, 111, 4965-4972.	0.6	38
140	Fibroblast Growth Factor-2 in Angiogenesis. , 2008, , 77-88.		2
141	Fibroblast Growth Factors/Fibroblast Growth Factor Receptors as Targets for the Development of Anti-Angiogenesis Strategies. Current Pharmaceutical Design, 2007, 13, 2025-2044.	0.9	134
142	Mammalian Tumor Xenografts Induce Neovascularization in Zebrafish Embryos. Cancer Research, 2007, 67, 2927-2931.	0.4	245
143	Osteopontin Overexpression Inhibits in Vitro Re-endothelialization via Integrin Engagement. Journal of Biological Chemistry, 2007, 282, 19676-19684.	1.6	27
144	The discovery of basic fibroblast growth factor/fibroblast growth factor-2 and its role in haematological malignancies. Cytokine and Growth Factor Reviews, 2007, 18, 327-334.	3.2	78

#	Article	IF	Citations
145	Dendritic cellâ€“endothelial cell cross-talk in angiogenesis. Trends in Immunology, 2007, 28, 385-392.	2.9	115
146	Bone morphogenic protein antagonist Drm/gremlin is a novel proangiogenic factor. Blood, 2007, 109, 1834-1840.	0.6	118
147	CEACAM1/VEGF crossâ€talk during neuroblastic tumour differentiation. Journal of Pathology, 2007, 211, 541-549.	2.1	7
148	The zebrafish/tumor xenograft angiogenesis assay. Nature Protocols, 2007, 2, 2918-2923.	5.5	218
149	Role of the soluble pattern recognition receptor PTX3 in vascular biology. Journal of Cellular and Molecular Medicine, 2007, 11, 723-738.	1.6	166
150	Cutting Edge: Extracellular High Mobility Group Box-1 Protein Is a Proangiogenic Cytokine. Journal of Immunology, 2006, 176, 12-15.	0.4	212
151	The gelatin spongeâ€“chorioallantoic membrane assay. Nature Protocols, 2006, 1, 85-91.	5.5	229
152	Identification of an Antiangiogenic FGF2-binding Site in the N Terminus of the Soluble Pattern Recognition Receptor PTX3. Journal of Biological Chemistry, 2006, 281, 22605-22613.	1.6	101
153	Extracellular Angiogenic Growth Factor Interactions: An Angiogenesis Interactome Survey. Endothelium: Journal of Endothelial Cell Research, 2006, 13, 93-111.	1.7	43
154	Cutting Edge: IL-1Î² Mediates the Proangiogenic Activity of Osteopontin-Activated Human Monocytes. Journal of Immunology, 2006, 177, 4267-4270.	0.4	97
155	Heparin Derivatives and Semisynthetic Biotechnological Heparins as Angiogenesis Inhibitors. Frontiers in Drug Design and Discovery, 2005, 2, 371-391.	0.3	0
156	FGF2-induced upregulation of DNA polymerase-Î´ p12 subunit in endothelial cells. Oncogene, 2005, 24, 1117-1121.	2.6	13
157	Regulated expression pattern of gremlin during zebrafish development. Gene Expression Patterns, 2005, 5, 539-544.	0.3	12
158	Antiangiogenic and Vascular-Targeting Activity of the Microtubule-Destabilizingtrans-Resveratrol Derivative 3,5,4â€²-Trimethoxystilbene. Molecular Pharmacology, 2005, 67, 1451-1459.	1.0	104
159	Biotechnological Engineering of Heparin/Heparan Sulphate: A Novel Area of Multi-Target Drug Discovery. Current Pharmaceutical Design, 2005, 11, 2489-2499.	0.9	52
160	Antiangiogenesis by Chemotherapeutic Agents. Mini-Reviews in Medicinal Chemistry, 2005, 5, 313-317.	1.1	7
161	Heparin Octasaccharides Inhibit Angiogenesis In vivo. Clinical Cancer Research, 2005, 11, 8172-8179.	3.2	61
162	Cutting Edge: Proangiogenic Properties of Alternatively Activated Dendritic Cells. Journal of Immunology, 2005, 175, 2788-2792.	0.4	124

#	Article	IF	Citations
163	Pentraxin 3 Inhibits Fibroblast Growth Factor 2â€“Dependent Activation of Smooth Muscle Cells In Vitro and Neointima Formation In Vivo. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 1837-1842.	1.1	93
164	Î±vÎ²3-integrin-dependent activation of focal adhesion kinase mediates NF-ÎºB activation and motogenic activity by HIV-1 Tat in endothelial cells. Journal of Cell Science, 2005, 118, 3949-3958.	1.2	47
165	Antiangiogenic Activity of Semisynthetic Biotechnological Heparins. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 71-76.	1.1	35
166	Integrin Î±VÎ²3as a Target for Blocking HIV-1 Tat-Induced Endothelial Cell Activation In Vitro and Angiogenesis In Vivo. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 2315-2320.	1.1	44
167	Biological and molecular properties of a new Î±vÎ²3/Î±vÎ²5 integrin antagonist. Molecular Cancer Therapeutics, 2005, 4, 1670-1680.	1.9	75
168	Complexity and Complementarity of Outer Membrane Protein A Recognition by Cellular and Humoral Innate Immunity Receptors. Immunity, 2005, 22, 551-560.	6.6	271
169	Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine and Growth Factor Reviews, 2005, 16, 159-178.	3.2	1,126
170	Undersulfated, low-molecular-weight glycol-split heparin as an antiangiogenic VEGF antagonist. Glycobiology, 2004, 15, 1C-6C.	1.3	48
171	Recombinant human erythropoietin induces intussusceptive microvascular growth in vivo. Leukemia, 2004, 18, 331-336.	3.3	52
172	Undersulfated and Glycol-Split Heparins Endowed with Antiangiogenic Activity. Journal of Medicinal Chemistry, 2004, 47, 838-848.	2.9	80
173	Chemically sulfatedEscherichia coliK5 polysaccharide derivatives as extracellular HIV-1 Tat protein antagonists. FEBS Letters, 2004, 568, 171-177.	1.3	50
174	Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis. Blood, 2004, 104, 92-99.	0.6	181
175	Erythropoietin as an angiogenic factor. European Journal of Clinical Investigation, 2003, 33, 891-896.	1.7	135
176	Distinct Role of Fibroblast Growth Factor-2 and Vascular Endothelial Growth Factor on Tumor Growth and Angiogenesis. American Journal of Pathology, 2003, 162, 1913-1926.	1.9	167
177	Overexpression of cytosolic sialidase Neu2 induces myoblast differentiation in C2C12 cells. FEBS Letters, 2003, 547, 183-188.	1.3	53
178	Fibroblast Growth Factor Receptor-1 Is Essential for In Vitro Cardiomyocyte Development. Circulation Research, 2003, 93, 414-420.	2.0	117
179	Osteopontin (Eta-1) and Fibroblast Growth Factor-2 Cross-Talk in Angiogenesis. Journal of Immunology, 2003, 171, 1085-1093.	0.4	123
180	Shedding of Membrane Vesicles Mediates Fibroblast Growth Factor-2 Release from Cells. Journal of Biological Chemistry, 2003, 278, 51911-51919.	1.6	99

#	Article	IF	Citations
181	Thrombospondin 1 as a scavenger for matrix-associated fibroblast growth factor 2. Blood, 2003, 102, 4399-4406.	0.6	93
182	Cross Talk between Haematopoiesis and Angiogenesis. Advances in Experimental Medicine and Biology, 2003, 522, 25-36.	0.8	4
183	Heparin Derivatives as Angiogenesis Inhibitors. Current Pharmaceutical Design, 2003, 9, 553-566.	0.9	102
184	Cell membrane GM1 ganglioside is a functional coreceptor for fibroblast growth factor 2. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 4367-4372.	3.3	101
185	Generation of Biologically Active Angiostatin Kringle 1â€“3 by Activated Human Neutrophils. Journal of Immunology, 2002, 168, 5798-5804.	0.4	125
186	Fibroblast Growth Factors and Their Receptors in Hematopoiesis and Hematological Tumors. Journal of Hematotherapy and Stem Cell Research, 2002, 11, 19-32.	1.8	52
187	Nerve growth factorâ€“endothelial cell interaction leads to angiogenesis in vitro and in vivo. FASEB Journal, 2002, 16, 1307-1309.	0.2	214
188	Pietro M. Gullino and Angiogenesis. Endothelium: Journal of Endothelial Cell Research, 2002, 9, 227-230.	1.7	2
189	Short Heparin Sequences Spaced by Glycol-Split Uronate Residues Are Antagonists of Fibroblast Growth Factor 2 and Angiogenesis Inhibitors. Biochemistry, 2002, 41, 10519-10528.	1.2	76
190	Arabinose-derived bicyclic amino acids: synthesis, conformational analysis and construction of an Î±vÎ²3-selective RGD peptide. Journal of the Chemical Society, Perkin Transactions 1, 2002, , 638-644.	1.3	15
191	The role of fibroblast growth factor-2 in the vascularization of the chick embryo chorioallantoic membrane. Journal of Cellular and Molecular Medicine, 2002, 6, 439-446.	1.6	29
192	Anti-angiogenic activity of the purine analog 6-thioguanine. Leukemia, 2002, 16, 1490-1499.	3.3	27
193	Gene expression profile in fibroblast growth factor 2-transformed endothelial cells. Oncogene, 2002, 21, 2433-2440.	2.6	30
194	Biological activity of substrate-bound basic fibroblast growth factor (FGF2): recruitment of FGF receptor-1 in endothelial cell adhesion contacts. Oncogene, 2002, 21, 3889-3897.	2.6	61
195	HIV-1 Tat protein and endothelium: from protein/cell interaction to AIDS-associated pathologies. Angiogenesis, 2002, 5, 141-151.	3.7	93
196	HIV-1 Tat protein: A target for the development of anti-AIDS therapies. Drugs of the Future, 2002, 27, 481.	0.0	21
197	Interaction of Angiogenic Growth Factors with Endothelial Cell Heparan Sulfate Proteoglycans. , 2002, , 357-385.		0
198	Activation of Endothelial Cell Mitogen Activated Protein Kinase ERK_{1/2}by Extracellular HIV-1 Tat Protein. Endothelium: Journal of Endothelial Cell Research, 2001, 8, 65-74.	1.7	40

#	Article	IF	Citations
199	Paracrine and autocrine effects of fibroblast growth factor-4 in endothelial cells. Oncogene, 2001, 20, 2655-2663.	2.6	53
200	Î±vÎ²3 integrin engagement modulates cell adhesion, proliferation, and protease secretion in human lymphoid tumor cells. Experimental Hematology, 2001, 29, 993-1003.	0.2	76
201	Internalization of HIV-1 Tat Requires Cell Surface Heparan Sulfate Proteoglycans. Journal of Biological Chemistry, 2001, 276, 3254-3261.	1.6	635
202	Cell-Mediated Delivery of Fibroblast Growth Factor-2 and Vascular Endothelial Growth Factor onto the Chick Chorioallantoic Membrane: Endothelial Fenestration and Angiogenesis. Journal of Vascular Research, 2001, 38, 389-397.	0.6	66
203	Fibroblast Growth Factor-2 Antagonist Activity and Angiostatic Capacity of Sulfated Escherichia coli K5 Polysaccharide Derivatives. Journal of Biological Chemistry, 2001, 276, 37900-37908.	1.6	73
204	Pentosan Polysulfate as an Inhibitor of Extracellular HIV-1 Tat. Journal of Biological Chemistry, 2001, 276, 22420-22425.	1.6	67
205	Modulation of tumor angiogenesis by conditional expression of fibroblast growth factor-2 affects early but not established tumors. Cancer Research, 2001, 61, 309-17.	0.4	42
206	Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist. Cancer Research, 2001, 61, 2232-8.	0.4	135
207	Inhibition of fibroblast growth factor-2-induced vascular tumor formation by the acyclic nucleoside phosphonate cidofovir. Cancer Research, 2001, 61, 5057-64.	0.4	33
208	An Italian pioneer in the study of tumor angiogenesis. Haematologica, 2001, 86, 1234-5.	1.7	2
209	The discovery of angiogenic factors:. General Pharmacology, 2000, 35, 227-231.	0.7	92
210	Thrombospondinâ€1/HIVâ€1 Tat protein interaction: modulation of the biological activity of extracellular Tat. FASEB Journal, 2000, 14, 1917-1930.	0.2	27
211	Role of fibroblast growth factorâ€2 in human brain: a focus on development. International Journal of Developmental Neuroscience, 2000, 18, 271-279.	0.7	38
212	Nerve growth factor induces sphingomyelin accumulation in pheochromocytoma cells. FEBS Letters, 2000, 472, 143-147.	1.3	2
213	Examining New Models for the Study of Autocrine and Paracrine Mechanisms of Angiogenesis Through FGF2-Transfected Endothelial and Tumour Cells. Advances in Experimental Medicine and Biology, 2000, 476, 7-34.	0.8	8
214	Comparative 3d-Morphometry of the Microvascular Unit In Tumors and Normal Tissues: Quantitative Studies on Corrosion Casts. Microscopy and Microanalysis, 1999, 5, 1198-1199.	0.2	0
215	Bone Marrow Neovascularization, Plasma Cell Angiogenic Potential, and Matrix Metalloproteinase-2 Secretion Parallel Progression of Human Multiple Myeloma. Blood, 1999, 93, 3064-3073.	0.6	537
216	Interaction of Fibroblast Growth Factor-2 (FGF-2) with Free Gangliosides: Biochemical Characterization and Biological Consequences in Endothelial Cell Cultures. Molecular Biology of the Cell, 1999, 10, 313-327.	0.9	65

#	Article	IF	Citations
217	Different Tyrosine Autophosphorylation Requirements in Fibroblast Growth Factor Receptor-1 Mediate Urokinase-Type Plasminogen Activator Induction and Mitogenesis. Molecular Biology of the Cell, 1999, 10, 23-33.	0.9	27
218	Modulation of Fibroblast Growth Factor-2 Receptor Binding, Signaling, and Mitogenic Activity by Heparin-Mimicking Polysulfonated Compounds. Molecular Pharmacology, 1999, 56, 204-213.	1.0	95
219	Multiple Interactions of HIV-I Tat Protein with Size-defined Heparin Oligosaccharides. Journal of Biological Chemistry, 1999, 274, 28198-28205.	1.6	110
220	Evidence for characteristic vascular patterns in solid tumours: quantitative studies using corrosion casts. British Journal of Cancer, 1999, 80, 724-732.	2.9	186
221	Endogenous and exogenous fibroblast growth factor-2 modulate wound healing in the chick embryo chorioallantoic membrane. Angiogenesis, 1999, 3, 89-95.	3.7	29
222	Thrombospondin-1 inhibits Kaposi's sarcoma (KS) cell and HIV-1 Tat-induced angiogenesis and is poorly expressed in KS lesions. , 1999, 188, 76-81.		44
223	Alterations of blood vessel development by endothelial cells overexpressing fibroblast growth factor-2. , 1999, 189, 590-599.		35
224	Alterations of blood vessel development by endothelial cells overexpressing fibroblast growth factor-2. , 1999, 189, 590.		3
225	Human Erythropoietin Induces a Pro-Angiogenic Phenotype in Cultured Endothelial Cells and Stimulates Neovascularization In Vivo. Blood, 1999, 93, 2627-2636.	0.6	461
226	Human Erythropoietin Induces a Pro-Angiogenic Phenotype in Cultured Endothelial Cells and Stimulates Neovascularization In Vivo. Blood, 1999, 93, 2627-2636.	0.6	16
227	Bone Marrow Neovascularization, Plasma Cell Angiogenic Potential, and Matrix Metalloproteinase-2 Secretion Parallel Progression of Human Multiple Myeloma. Blood, 1999, 93, 3064-3073.	0.6	119
228	Role of endothelial cell extracellular signal-regulated kinase1/2 in urokinase-type plasminogen activator upregulation and in vitro angiogenesis by fibroblast growth factor-2. Journal of Cell Science, 1999, 112, 2597-2606.	1.2	39
229	In vivo angiogenic activity of urokinase: role of endogenous fibroblast growth factor-2. Journal of Cell Science, 1999, 112, 4213-4221.	1.2	58
230	Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood, 1999, 93, 2627-36.	0.6	145
231	Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood, 1999, 93, 3064-73.	0.6	166
232	Purine analogue 6-methylmercaptopurine riboside inhibits early and late phases of the angiogenesis process. Cancer Research, 1999, 59, 2417-24.	0.4	47
233	Role of endothelial cell extracellular signal-regulated kinase1/2 in urokinase-type plasminogen activator upregulation and in vitro angiogenesis by fibroblast growth factor-2. Journal of Cell Science, 1999, 112 (Pt 15), 2597-606.	1.2	9
234	Developmentally regulated expression and localization of fibroblast growth factor receptors in the human muscle. , 1998, 211, 362-373.		19

#	Article	IF	Citations
235	Human lymphoblastoid cells produce extracellular matrix-degrading enzymes and induce endothelial cell proliferation, migration, morphogenesis, and angiogenesis. International Journal of Clinical and Laboratory Research, 1998, 28, 55-68.	1.0	85
236	The Basic Domain in HIV-1 Tat Protein as a Target for Polysulfonated Heparin-mimicking Extracellular Tat Antagonists. Journal of Biological Chemistry, 1998, 273, 16027-16037.	1.6	105
237	Noncompetitive, Chemokine-mediated Inhibition of Basic Fibroblast Growth Factor-induced Endothelial Cell Proliferation. Journal of Biological Chemistry, 1998, 273, 7911-7919.	1.6	15
238	Characterization of the Effects of Two Polysulfonated Distamycin A Derivatives, PNU145156E and PNU153429, on HIV Type 1 Tat Protein. AIDS Research and Human Retroviruses, 1998, 14, 1561-1571.	0.5	16
239	Autocrine Role of Basic Fibroblast Growth Factor (bFGF) in Angiogenesis and Angioproliferative Diseases. , 1998, , 99-112.		0
240	Impact of fibroblast growth factor-2 on tumor microvascular architecture. A tridimensional morphometric study. American Journal of Pathology, 1998, 152, 1607-16.	1.9	36
241	Role of basic fibroblast growth factor in the formation of the capillary plexus in the chick embryo chorioallantoic membrane. An in situ hybridization, immunohistochemical and ultrastructural study. Journal of Submicroscopic Cytology and Pathology, 1998, 30, 127-36.	0.3	14
242	Î±_vÎ²₃Integrin Mediates the Cell-adhesive Capacity and Biological Activity of Basic Fibroblast Growth Factor (FGF-2) in Cultured Endothelial Cells. Molecular Biology of the Cell, 1997, 8, 2449-2461.	0.9	140
243	Upregulation of urokinase-type plasminogen activator by endogenous and exogenous HIV-1 Tat protein in tumour cell lines derived from BK virus/tat-transgenic mice. Aids, 1997, 11, 727-736.	1.0	8
244	Interaction of HIV-1 Tat Protein with Heparin. Journal of Biological Chemistry, 1997, 272, 11313-11320.	1.6	179
245	New Model for the Study of Angiogenesis and Antiangiogenesis in the Chick Embryo Chorioallantoic Membrane: The Gelatin Sponge/ Chorioallantoic Membrane Assay. Journal of Vascular Research, 1997, 34, 455-463.	0.6	199
246	Basic Fibroblast Growth Factor-Induced Angiogenesis in the Chick Embryo Chorioallantoic Membrane: An Electron Microscopy Study. Microvascular Research, 1997, 53, 187-190.	1.1	13
247	Urokinase-Type Plasminogen Activator Overexpression Enhances the Invasive Capacity of Endothelial Cells. Microvascular Research, 1997, 53, 254-260.	1.1	17
248	Endothelial cells overexpressing basic fibroblast growth factor (FGF-2) induce vascular tumors in immunodeficient mice. Angiogenesis, 1997, 1, 102-116.	3.7	25
249	The italian 'Special Project on Angiogenesis'. Angiogenesis, 1997, 1, 20-21.	3.7	0
250	Basic Fibroblast Growth Factorâ€“Induced Angiogenic Phenotype in Mouse Endothelium. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 454-464.	1.1	108
251	Nitric Oxide Promotes Proliferation and Plasminogen Activator Production by Coronary Venular Endothelium Through Endogenous bFGF. Circulation Research, 1997, 80, 845-852.	2.0	182
252	The 140-kilodalton antiangiogenic fragment of thrombospondin-1 binds to basic fibroblast growth factor. Cell Growth & Differentiation: the Molecular Biology Journal of the American Association for Cancer Research, 1997, 8, 471-9.	0.8	29

#	Article	IF	Citations
253	Role of soluble mediators in angiogenesis. European Journal of Cancer, 1996, 32, 2401-2412.	1.3	76
254	Clinical studies with angiogenesis inhibitors: Biological rationale and challenges for their evaluation. Annals of Oncology, 1996, 7, 441-444.	0.6	28
255	Basic fibroblast growth factor modulates in vitro differentiation of human fetal microglia. NeuroReport, 1996, 7, 2813-2818.	0.6	13
256	Promotion of tumour metastases and induction of angiogenesis by native HIV-1 Tat protein from BK virus/tat transgenic mice. Aids, 1996, 10, 701-710.	1.0	42
257	Up-regulation of urokinase-type plasminogen activator in squamous cell carcinoma of human larynx. British Journal of Cancer, 1996, 74, 1168-1174.	2.9	18
258	Interaction of angiogenic basic fibroblast growth factor with endothelial cell heparan sulfate proteoglycans. International Journal of Clinical and Laboratory Research, 1996, 26, 15-23.	1.0	121
259	A distinct basic fibroblast growth factor (FGF-2)/FGF receptor interaction distinguishes urokinase-type plasminogen activator induction from mitogenicity in endothelial cells.. Molecular Biology of the Cell, 1996, 7, 369-381.	0.9	39
260	Angiogenic phenotype induced by basic fibroblast growth factor transfection in brain microvascular endothelial cells. International Journal of Oncology, 1996, 8, 567-573.	1.4	6
261	Basic Fibroblast Growth Factor Expression in Endothelial Cells: An Autocrine Role in Angiogenesis?. , 1996, , 61-72.		2
262	The Interaction of Basic Fibroblast Growth Factor (bFGF) With Heparan Sulfate Proteoglycans. , 1996, , 171-187.		1
263	HIV-tat protein is a heparin-binding angiogenic growth factor. Oncogene, 1996, 12, 289-97.	2.6	125
264	Basic fibroblast growth factor overexpression in endothelial cells: an autocrine mechanism for angiogenesis and angioproliferative diseases. Cell Growth & Differentiation: the Molecular Biology Journal of the American Association for Cancer Research, 1996, 7, 147-60.	0.8	22
265	Transcriptional and posttranscriptional regulation of urokinase-type plasminogen activator expression in endothelial cells by basic fibroblast growth factor. Journal of Cellular Physiology, 1995, 162, 400-409.	2.0	42
266	MECHANISMS OF KAPOSIS-SARCOMA CELL SUPERNATANT-INDUCED VASCULAR CELL INVASION. International Journal of Oncology, 1995, 6, 539-46.	1.4	0
267	Inhibition of inducible nitric oxide synthase mRNA expression by basic fibroblast growth factor in human microglial cells. Neuroscience Letters, 1995, 195, 45-48.	1.0	28
268	Expression of basic fibroblast growth factor and its receptors in human fetal microglia cells. International Journal of Developmental Neuroscience, 1995, 13, 29-39.	0.7	44
269	Endogenous Basic Fibroblast Growth Factor Is Implicated in the Vascularization of the Chick Embryo Chorioallantoic Membrane. Developmental Biology, 1995, 170, 39-49.	0.9	158
270	Growth advantage and vascularization induced by basic fibroblast growth factor overexpression in endometrial HEC-1-B cells: an export-dependent mechanism of action. Cancer Research, 1995, 55, 4729-38.	0.4	30

#	Article	IF	Citations
271	Elucidation of a signaling pathway induced by FGF-2 leading to uPA gene expression in NIH 3T3 fibroblasts. Cell Growth & Differentiation: the Molecular Biology Journal of the American Association for Cancer Research, 1995, 6, 1009-17.	0.8	16
272	Evaluation of the tumor-promoting activity of two Î²-adrenoreceptor blocking agents, propranolol and atenolol, in liver of Fischer 344 rats. Carcinogenesis, 1994, 15, 2531-2539.	1.3	16
273	Inhibition of angiogenesis in rats by IL-1 receptor antagonist and selected cytokine antibodies. Inflammation, 1994, 18, 45-58.	1.7	39
274	Interaction of high-molecular-weight basic fibroblast growth factor with endothelium: Biological activity and intracellular fate of human recombinant Mr 24,000 bFGF. Journal of Cellular Physiology, 1994, 161, 149-159.	2.0	66
275	Distinct Role of 2-O-, N-, and 6-O-Sulfate Groups of Heparin in the Formation of the Ternary Complex with Basic Fibroblast Growth Factor and Soluble FGF Receptor-1. Biochemical and Biophysical Research Communications, 1994, 203, 450-458.	1.0	85
276	Different effects of mucosal, bovine lung and chemically modified heparin on selected biological properties of basic fibroblast growth factor. Biochemical Journal, 1994, 303, 583-590.	1.7	40
277	Differential expression of fibroblast growth factor receptors by human neurones, astrocytes, and microglia. NeuroReport, 1994, 6, 197-200.	0.6	29
278	Human Basic Fibroblast Growth Factor: Structure-Function Relationship of an Angiogenic Molecule. , 1994, , 39-50.		0
279	Basic fibroblast growth factor in human pheochromocytoma: A biochemical and immunohistochemical study. International Journal of Cancer, 1993, 53, 5-10.	2.3	33
280	Internalization of basic fibroblast growth factor (bFGF) in cultured endothelial cells: Role of the low affinity heparin-like bFGF receptors. Journal of Cellular Physiology, 1993, 154, 152-161.	2.0	85
281	Biochemical bases of the interaction of human basic fibroblast growth factor with glycosaminoglycans. New insights from trypsin digestion studies. FEBS Journal, 1993, 214, 51-58.	0.2	52
282	Estro-Progestinic Replacement Therapy Modulates the Levels of Basic Fibroblast Growth Factor (bFGF) in Postmenopausal Endometrium. Gynecologic Oncology, 1993, 48, 88-93.	0.6	22
283	Subcellular Localization and Biological Activity of Mr 18,000 Basic Fibroblast Growth Factor: Site-Directed Mutagenesis of a Putative Nuclear Translocation Sequence. Growth Factors, 1993, 9, 269-278.	0.5	17
284	The NH2-Terminal Extension of High Molecular Weight Forms of Basic Fibroblast Growth Factor (bFGF) is not Essential for the Binding of bFGF to Nuclear Chromatin in Transfected NIH 3T3 Cells. Growth Factors, 1993, 8, 49-60.	0.5	23
285	Basic fibroblast growth factor modulates integrin expression in microvascular endothelial cells.. Molecular Biology of the Cell, 1993, 4, 973-982.	0.9	195
286	Structure-function relationship of basic fibroblast growth factor: Site-directed mutagenesis of a putative heparin-binding and receptor-binding region. Biochemical and Biophysical Research Communications, 1992, 185, 1098-1107.	1.0	31
287	Activation of the tyrosine kinase receptor is not sufficient for the full biological activity of bFGF. Exs, 1992, 61, 101-106.	1.4	3
288	Basic Fibroblast Growth Factor and Endothelial Cells: Receptor Interaction, Signal Transduction, Cellular Response-Dissociation of the Mitogenic Activity of bFGF from its Plasminogen Activator-Inducing Capacity. , 1992, , 79-89.		0

#	Article	IF	Citations
289	Basic fibroblast growth factor bound to cell substrate promotes cell adhesion, proliferation, and protease production in cultured endothelial cells. Exs, 1992, 61, 205-209.	1.4	8
290	Nuclear localization of endogenous basic fibroblast growth factor in cultured endothelial cells. Experimental Cell Research, 1991, 192, 505-510.	1.2	62
291	Functional Domains of Basic Fibroblast Growth Factor: Possible Role of Asp-Gly-Arg Sequences in the Mitogenic Activity of bFGF. Annals of the New York Academy of Sciences, 1991, 638, 361-368.	1.8	6
292	A Mutant of Basic Fibroblast Growth Factor that Has Lost the Ability to Stimulate Plasminogen Activator Synthesis in Endothelial Cells. Annals of the New York Academy of Sciences, 1991, 638, 369-377.	1.8	3
293	Immunoreactive Basic Fibroblast Growth Factor-Like Proteins in Chromaffin Granules. Journal of Neurochemistry, 1991, 56, 1087-1088.	2.1	10
294	Biologically active synthetic fragments of human basic fibroblast growth factor (bFGF): Identification of two Asp-Gly-Arg-Containing domains involved in the mitogenic activity of bFGF in endothelial cells. Journal of Cellular Physiology, 1991, 149, 512-524.	2.0	32
295	Basic fibroblast growth factor requires a long-lasting activation of protein kinase C to induce cell proliferation in transformed fetal bovine aortic endothelial cells.. Molecular Biology of the Cell, 1991, 2, 719-726.	6.5	64
296	A six-amino acid deletion in basic fibroblast growth factor dissociates its mitogenic activity from its plasminogen activator-inducing capacity.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 2628-2632.	3.3	76
297	Is the Beta-Blocker DL-ZAMI 1305 a Tumor Promoter for Rat Liver?. , 1991, , 599-610.		0
298	Synthesis of Urokinase-Type Plasminogen Activator and of Type- 1 Plasminogen Activator Inhibitor in Neuronal Cultures of Human Fetal Brain: Stimulation by Phorbol Ester. Journal of Neurochemistry, 1990, 55, 1647-1654.	2.1	31
299	Basic fibroblast growth factor in neuronal cultures of human fetal brain. Journal of Neuroscience Research, 1990, 27, 78-83.	1.3	26
300	Chemical structure and genotoxic activity of the hepatocarcinogenic beta-blocker DL-ZAMI 1305. Carcinogenesis, 1990, 11, 261-265.	1.3	3
301	Basic Fibroblast Growth Factor in Ovulatory Cycle and Postmenopausal Human Endometrium. Growth Factors, 1990, 3, 299-307.	0.5	49
302	Liver genotoxic activity of an epoxide derivative of the hepatocarcinogenic Î²-blocker DL-ZAMI 1305. Cancer Letters, 1990, 55, 61-66.	3.2	0
303	Characterization of a Mr 20,000 basic fibroblast growth factor-like protein secreted by normal and transformed fetal bovine aortic endothelial cells. Experimental Cell Research, 1990, 186, 354-361.	1.2	24
304	Basic fibroblast growth factor is released from endothelial extracellular matrix in a biologically active form. Journal of Cellular Physiology, 1989, 140, 68-74.	2.0	137
305	Basic fibroblast growth factor: Production, mitogenic response, and post-receptor signal transduction in cultured normal and transformed fetal bovine aortic endothelial cells. Journal of Cellular Physiology, 1989, 141, 517-526.	2.0	50
306	Characterization of a Mr 25,000 basic fibroblast growth factor form in adult, regenerating, and fetal rat liver. Biochemical and Biophysical Research Communications, 1989, 164, 1182-1189.	1.0	41

#	Article	IF	Citations
307	Induction of plasminogen activator activity by phorbol ester in transformed fetal bovine aortic endothelial cells. Possible independence from protein kinase C. Biochemical and Biophysical Research Communications, 1989, 160, 682-691.	1.0	11
308	The mitogenic signaling pathway but not the plasminogen activator-inducing pathway of basic fibroblast growth factor is mediated through protein kinase C in fetal bovine aortic endothelial cells.. Journal of Cell Biology, 1989, 109, 1877-1884.	2.3	126
309	Sex hormones modulate the synthesis of basic fibroblast growth factor in human endometrial adenocarcinoma cells: Implications for the neovascularization of normal and neoplastic endometrium. Journal of Cellular Physiology, 1988, 137, 593-597.	2.0	86
310	Multiple forms of an angiogenesis factor: basic fibroblast growth factor. Biochimie, 1988, 70, 83-87.	1.3	54
311	Purification of basic fibroblast growth factor from rat brain: Identification of a Mr 22,000 immunoreactive form. Biochemical and Biophysical Research Communications, 1988, 155, 1161-1172.	1.0	57
312	High molecular weight immunoreactive basic fibroblast growth factor-like proteins in rat pituitary and brain. Neuroscience Letters, 1988, 90, 308-313.	1.0	34
313	New Aspects of Blood Vessel Growth: Tumor and Tissue-Derived Angiogenesis Factors. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1988, 18, 6-17.	0.5	9
314	Liver DNA Damage by Chemical Carcinogens: Role of Thyroid Hormones. , 1988, , 129-135.		1
315	Modulation of plasminogen activator activity in human endometrial adenocarcinoma cells by basic fibroblast growth factor and transforming growth factor beta. Cancer Research, 1988, 48, 6384-9.	0.4	34
316	A form of human basic fibroblast growth factor with an extended amino terminus. Biochemical and Biophysical Research Communications, 1987, 144, 543-550.	1.0	112
317	Critical role of gonadal hormones on the genotoxic activity of the hepatocarcinogen DL-ZAMI 1305. Cancer Letters, 1987, 36, 253-261.	3.2	5
318	Purification of a factor from human placenta that stimulates capillary endothelial cell protease production, DNA synthesis, and migration.. Proceedings of the National Academy of Sciences of the United States of America, 1986, 83, 2091-2095.	3.3	335
319	Purification from a human hepatoma cell line of a basic fibroblast growth factor-like molecule that stimulates capillary endothelial cell plasminogen activator production, DNA synthesis, and migration.. Molecular and Cellular Biology, 1986, 6, 4060-4066.	1.1	270
320	Both normal and tumor cells produce basic fibroblast growth factor. Journal of Cellular Physiology, 1986, 129, 273-276.	2.0	234
321	Further Studies on the Tumor-Initiating Activity of the Beta-Blocker DL-ZAMI 1305. Toxicologic Pathology, 1986, 14, 470-476.	0.9	1
322	Purification from a human hepatoma cell line of a basic fibroblast growth factor-like molecule that stimulates capillary endothelial cell plasminogen activator production, DNA synthesis, and migration. Molecular and Cellular Biology, 1986, 6, 4060-4066.	1.1	74
323	Purification and biological activities of an angiogenesis factor from human placenta. Anticancer Research, 1986, 6, 861-3.	0.5	9
324	Human placental tissue stimulates bovine capillary endothelial cell growth, migration and protease production. Bioscience Reports, 1985, 5, 783-790.	1.1	25

#	Article	IF	Citations
325	Inhibition of DNA and RNA Synthesis in Rat Liver Nuclei by Oncogenic and Non-oncogenic Î²-Blockers. Toxicologic Pathology, 1985, 13, 18-25.	0.9	6
326	Thyroid and Chemical Hepatocarcinogenesis: Further Insights from the Hepatocarcinogen Zami 1305. Toxicologic Pathology, 1984, 12, 49-55.	0.9	2
327	Early liver alterations induced by the sex-dependent hepatocarcinogen Î²-blocker ZAMI 1305. Chemico-Biological Interactions, 1984, 52, 203-212.	1.7	3
328	Optical isomers of the hepatocarcinogenic Î²-blocker zami 1305: Influence on nucleic acids synthesis and DNA integrity. Chemico-Biological Interactions, 1984, 50, 77-86.	1.7	5
329	Age-dependent, seasonal and daily variations of the DNA damaging capacity of the hepatocarcinogen ZAMI 1305 in female rat liver. Cancer Letters, 1984, 23, 245-251.	3.2	5
330	Tumor-initiating activity of the beta-blocker ZAMI 1305 in the liver of the female Wistar rat. Cancer Letters, 1984, 25, 1-11.	3.2	6
331	Embryonic---Fetal Hb switch in humans: studies on erythroid bursts generated by embryonic progenitors from yolk sac and liver.. Proceedings of the National Academy of Sciences of the United States of America, 1984, 81, 2416-2420.	3.3	60
332	In vitro inhibition of rat liver DNA polymerases Î± and Î² by Î²-blockers. Bioscience Reports, 1983, 3, 299-308.	1.1	5
333	Thyroid modifications in male and female rats treated with the hepatocarcinogen beta-blocker ZAMI 1305. Cancer Letters, 1983, 19, 293-299.	3.2	4
334	In vitro and in vivo DNA damage of male and female rat liver nuclei by oncogenic and nononcogenic beta blockers. Journal of the National Cancer Institute, 1983, 70, 747-52.	3.0	16
335	Cellular and molecular mechanisms of the human embryonic leads to fetal hemoglobin switch. Progress in Clinical and Biological Research, 1983, 134, 411-9.	0.2	0
336	Preferential induction of fetal versus embryonic globin chains in human leukemic cell lines. Leukemia Research, 1982, 6, 155-163.	0.4	7
337	Inhibition in vitro of yeast DNA polymerase I activity by beta-blockers. Bioscience Reports, 1982, 2, 55-62.	1.1	4
338	Liver tumors induced by a new beta-adrenoreceptor blocking agent in female rats. Journal of the National Cancer Institute, 1982, 68, 669-72.	3.0	19
339	Liver growth after partial hepatectomy: Influence of phenobarbital administration. Experimental and Molecular Pathology, 1981, 34, 216-225.	0.9	2
340	Quantification of damage to striated muscle after normothermic or hypothermic ischemia. Clinical Chemistry, 1981, 27, 297-302.	1.5	8
341	Decrease of the activity of the mixed function oxidase system in regenerating rat liver: An alternative explanation. Biochemical and Biophysical Research Communications, 1980, 95, 829-834.	1.0	19
342	Inhibition of protein synthesis in ischaemic liver from phenobarbitone-treated rat. Experientia, 1979, 35, 86-88.	1.2	3

#	Article	IF	Citations
343	Gene expression profile in fibroblast growth factor 2-transformed endothelial cells. , 0, .		1